Vaccines - France

France

In France, the Vaccines market is forecasted to achieve a revenue of €2,203.00m by 2024.
Furthermore, it is expected that the revenue will experience a compounded annual growth rate (CAGR 2024-2029) of 0.46%, leading to a market volume of €2,254.00m by 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue in the Vaccines market, reaching an estimated value of €27,010.00m in 2024.
In France, the demand for vaccines has surged in recent years, driven by a strong emphasis on public health and a proactive approach to disease prevention.

Key regions: Australia, Italy, France, South Korea, Brazil

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Vaccines market in France has seen significant growth in recent years.

Customer preferences: French customers have become increasingly aware of the importance of vaccination in preventing diseases. This has led to an increase in demand for vaccines, especially for children. In addition, the French government has implemented a mandatory vaccination policy for children, which has further boosted the demand for vaccines.

Trends in the market: One of the major trends in the French Vaccines market is the increasing popularity of combination vaccines. Combination vaccines offer multiple vaccines in a single shot, reducing the number of injections required and making the vaccination process more convenient. In addition, there has been a growing demand for vaccines that offer long-term protection against diseases.

Local special circumstances: France has a highly centralized healthcare system, with the government playing a significant role in the provision and funding of healthcare services. This has led to a high level of regulation in the Vaccines market, with strict rules governing the approval, pricing, and reimbursement of vaccines. In addition, the French government has a strong focus on public health, which has led to a high level of investment in vaccination programs.

Underlying macroeconomic factors: The French economy has been growing steadily in recent years, with low unemployment and high levels of consumer confidence. This has led to an increase in healthcare spending, including spending on vaccines. In addition, the French healthcare system is highly advanced, with a strong focus on research and development. This has led to the development of innovative vaccines that are in high demand both in France and globally.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.